Scipio bioscience is a biotechnology company developing a new generation of single-cell sequencing solutions.
Scipio Bioscience provides a novel sample preparation solution for single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics.
Scipio Bioscience was founded in 2017 by Stuart Edelstein and Pierre Walrafen. The company is headquartered in Paris, France.
Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. Based on a novel combination of established biochemical and biophysical approaches, the Scipio technology achieves single-cell barcoding in a test tube format.
Scipio Bioscience hosted in the iPEPS-ICM incubator of the Brain & Spine Institute (ICM, Pitié-Salpêtrière Hospital, Paris), has developed the protocol from the initial proof-of-concept studies to a prototype kit ready for beta-testing by collaborating research teams.
Scipio Bioscience is backed by M Ventures, M Ventures (Amsterdam, The Netherlands), Seventure Partners’ Quadrivum I (Paris, France) and others. The company raised €6M in a Series A round on Feb 25, 2020. This brings Scipio's total funding to €7.2M to date.